Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Filler, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Filler, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2003) 18: VI75-VI78
© 2003 European Renal Association-European Dialysis and Transplant Association

Treatment of nephrotic syndrome in children and controlled trials

Guido Filler

Department of Paediatrics, Division of Nephrology, Children’s Hospital of Eastern Ontario, University of Ottawa, Canada

Correspondence and offprint requests to: Guido Filler, MD, PhD, FRCPC, Professor of Paediatrics, Department of Paediatrics, University of Ottawa, 401 Smyth Road, Ottawa, Ontario, Canada K1H 8LI. Email: filler{at}cheo.on.ca

Abstract

Aim. To determine the sequential therapy of childhood nephrotic syndrome (NS) with presumed minimal change nephropathy using the evidence from clinical trials.

Methods. Meta-analysis of 22 randomized controlled trials was performed, using frequency of relapse and side effects of therapeutic regimes.

Results. A meta-analysis of seven trials comparing duration of therapy for initial onset showed that duration of at least 3 months significantly reduced the risk of relapse at 12–24 months (relative risk 0.73; 95% confidence interval 0.60–0.89) without an increase in adverse events. Five trials were performed for steroid treatment of relapse. Deflazacort reduced relapses during therapy, but is not generally available. No difference was observed when comparing single and divided dosing of prednisone. Frequency of relapses could not be influenced by duration of relapse therapy. Alternate day therapy was more effective than intermittent use of prednisone. Two studies out of five on cyclophosphamide or chlorambucil showed consistently that alkylating agents should be used before cyclosporine as alternative therapy to steroids.

Conclusions. Children with initial onset of NS should be treated with prednisone at a dose of 60 mg/m2/day for 6 weeks, followed by a dose of 40 mg/m2/48 h for at least another 6 weeks. If steroid toxicity for treatment of relapsing NS requires alternative treatment, cyclophosphamide (2 mg/kg/day for at least 8 weeks) remains the drug of choice with a curative potential. If children still relapse after alkylating agents, levamisole may serve as an alternative only for frequent relapsing NS, whereas steroid-dependent NS should be treated with cyclosporine.

Keywords: children; chlorambucil; controlled trials; corticosteroid therapy; cyclophosphamide; cyclosporine; meta-analysis; nephrotic syndrome; treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.